Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Factor Xa inhibitors: today and beyond.

Jeanine M Walenga¹, Walter P Jeske, Debra Hoppensteadt

¹Departments of Pathology and Thoracic-Cardiovascular Surgery, Loyola University Medical Center, 2160 S First Avenue, Maywood, IL 60153, USA. jwaleng@lumc.edu

Current Opinion in Investigational Drugs (London, England : 2000)

|May 9, 2003

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Thromboinflammation and hemostatic activation drive early mortality risk in pulmonary embolism.

Research and practice in thrombosis and haemostasis·2026

Same author

Multicenter Evaluation of a New Strip-Based Blood Glucose System for Point-of-Care Testing in Critical and Non-Critical Care Settings.

Journal of diabetes science and technology·2025

Same author

Vascular Endothelial Dysfunction and Immunothrombosis in the Pathogenesis of Atrial Fibrillation.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·2024

Same author

Decreased Thrombin Generation is Associated with Increased Thrombin Generation Biomarkers and Blood Cellular Indices in Pulmonary Embolism.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·2024

Same author

Thromboinflammatory Biomarkers of Cardiorenal Syndrome in Patients With End-Stage Renal Disease.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·2024

Same author

Andexanet Alfa Neutralizes the Anticoagulant Effects of Unfractionated Heparin of Bovine, Ovine and Porcine Origin Almost as Protamine Sulfate.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·2024

Serine proteases, like Factor Xa, are key in blood clot formation. Inhibiting Factor Xa is a promising strategy for developing new antithrombotic drugs to prevent heart attack and stroke.

Area of Science:

Biochemistry
Hematology
Pharmacology

Background:

Serine proteases are crucial enzymes in thrombogenesis, the process of blood clot formation.
Factor Xa, a serine protease, plays a central role in the coagulation cascade and platelet activation.
Thrombin generation, leading to fibrin clot formation, is downstream of Factor Xa activity.

Purpose of the Study:

To highlight the significance of Factor Xa in thrombogenesis.
To underscore the therapeutic potential of inhibiting Factor Xa and its generation.
To inform the development of novel antithrombotic agents.

Main Methods:

Review of coagulation cascade mechanisms.
Analysis of Factor Xa's role in thrombin formation.

Related Experiment Videos

Evaluation of Factor Xa inhibition as an antithrombotic strategy.

Main Results:

Factor Xa is a critical enzyme in the prothrombinase complex, essential for thrombin generation.
The inhibition of Factor Xa and its upstream generation directly impacts fibrin clot formation.
Targeting Factor Xa presents a viable approach for antithrombotic drug development.

Conclusions:

Factor Xa is a pivotal target for antithrombotic therapies.
Inhibiting Factor Xa offers a strategic pathway to manage thrombotic disorders like heart attack and stroke.
Further research into Factor Xa inhibitors is warranted for cardiovascular disease prevention.